This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Ask the Experts: Optimizing Immunotherapy for Cancer Patients: A Focus on Dosing and Special Populations

Ask the Experts: Optimizing Immunotherapy for Cancer Patients: A Focus on Dosing and Special Populations

Format

Slide Lecture Series

Time to Complete

1 hour

Released

May 25, 2018

Expires

May 25, 2019
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Pharmacy Credits

Pharmacists may earn 1.00 CPE Credit (0.10 CEUs) by completing this course on the American Society of Health-System Pharmacists (ASHP) website. Please click here to go to the course (you will leave the myCME website, and free registration on the ASHP website is required). Your certificate will save on ASHP.org and will not be included in your myCME CME History.

Accredited Provider

This continuing medical education activity is provided by the American Society of Health-System Pharmacists (ASHP).

Commercial Supporter

Supported by an educational grant from Merck

Program Description

This educational activity will focus on the role of PD-1 and PD-L1 inhibitors and their role in treating patients with cancer and clinical evidence and cost of individualized and flat dosing of PD-1 and PD-L1 inhibitors. Clinical evidence supporting the use of PD-1 and PD-L1 inhibitors in cancer patients with comorbidities related to organ dysfunction and altered immunity will also be discussed.

The content for this activity is based on questions and comments from participants at a recent educational symposium on this topic.

Intended Audience

This activity was planned to meet the educational needs of physicians, pharmacists, physician assistants, and nurse practitioners who are interested in immunotherapies and their role in cancer treatment.

Educational Objectives

At the conclusion of this application-based educational activity, participants should be able to:

  • Review the pharmacology and pharmacokinetics of PD-1 and PD-L1 inhibitors.
  • Compare and contrast the clinical evidence and cost of individualized and flat dosing of PD-1 and PD- L1 inhibitors.
  • Discuss the evidence supporting the use of PD-1 and PD-L1 inhibitors in cancer patients with comorbidities related to organ dysfunction and altered immunity.

Conflict Of Interest Disclosure Policy

In accordance with ACCME and ACPE Standards for Commercial Support, ASHP policy requires that all faculty, planners, reviewers, staff, and others in a position to control the content of this presentation disclose their financial relationships. In this activity, only the individuals below have disclosed a relevant financial relationship. No other persons associated with this presentation have disclosed any relevant financial relationships.

Faculty

Christine M. Walko, PharmD, BCOP, FCCP, Activity Chair
Personalized Medicine Specialist
DeBartolo Family Personalized Medicine Institute
Moffitt Cancer Center
Associate Professor
University of South Florida Morsani College of Medicine
Tampa, FL

Dr. Walko discloses the following:
Bristol-Myers Squibb and Merck: Honoraria received for participation in the Institute for Clinical Immuno-Oncology’s Melanoma Board

Ragini R. Kudchadkar, MD
Associate Professor
Winship Cancer Institute of Emory University
Associate Director Hematology/Oncology Fellowship Program
Atlanta, GA

Dr. Kudchadkar discloses the following:
Bristol-Myers Squibb: Advisory Board member
Merck: Research funding received

Accredited Provider Disclosure

The planners and managers reported no financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of this CME activity.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

The American Society of Health-System Pharmacists is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation Statement

The American Society of Health-System Pharmacists designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM  . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.

Instructions

In order to receive credit, participants must complete the post-test and program evaluation. Participants must also score at least 70% on the post-test. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

For information about the accreditation of this program, please contact elearning@ashp.org.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue